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Test article and administration
CDDP (Lot No. 076K1697, Sigma-Aldrich Co., St. Louis, MO, USA) was dissolved in physiological saline and administered intraperitoneally at dose levels of 0.25, 0.5, 1.0 and 2.0 mg/kg for the 2-week study; 0.125, 0.25 and 0.5 mg/kg for the 4-week study; and 0.25, 0.5 and 1.0 mg/kg for the female fertility study. The dosing volume was 5 ml/kg in each study. The dosing period in the 2-and 4-week studies was 14 days and 28 days, respectively. In the female fertility study, the dosing period was from 14 days prior to the initiation of mating, throughout the mating period until Day 7 of gestation. The control animals received the same dose of physiological saline for the same period in each study.
Repeated-dose toxicity studies (2-or 4-week studies)
Observations and examinations ing. The animals were observed daily for clinical signs and mortality, and their estrous cycle was checked using vaginal smears in the late half of the dosing period. Body weight and food consumption were recorded once or twice weekly. After being euthanized by exsanguination under anesthesia with diethyl ether inhalation at the end of the dosing period, the ovaries and uterus were removed and weighed, and then these organs as well as the vagina were ovaries were transversely halved to observe the maximum area for light microscopy. Hematoxylin and eosin (H&E) were made for histopathological examination. Additional sections of the ovaries were stained immunohistochemically using anti-proliferating cell nuclear antigen (PCNA, clone: PC10, DakoCytomation Denmark A/S, Glostrup, Denmark, dilution 1:800) to allow easy observation of the primordial follicle (Muskhelishvili et al., 2005) . Ovarian follicles were divided into the following three groups with reference to the previous report (Pedersen and Peters, 1968) : small follicles, type 1 to 3ab of Pedersen's classitype 5b to 8. The criteria for the decrease in follicle were as follows: +, several follicles were seen in the specimen; ++, few follicles were seen; +++, no follicles were seen. The criteria for the increase in atresia were as follows: +, atresia in about 50% follicles; ++, atresia in more than 50%; +++, atresia in almost all follicles. 
Observations and examinations
ing, and the day of copulation was regarded as Day 0 of gestation. The animals were observed daily for clinical signs and mortality, and their estrous cycle was checked using vaginal smears from the initiation of dosing until the day of copulation. Body weight was recorded twice weekly in the pre-mating period and once daily in the gestation period. Two females were mated with one nontreated male from Day 13 of dosing until the day of copin the vaginal smear or the vaginal plug. The copulation index (the number of animals that successfully copulated/the number of mated animals ×100), fertility index (the number of pregnant animals/the number of animals that successfully copulated ×100) and pre-coital period (the number of days between the initiation of mating and copulation) were calculated for each group. The copulated females were euthanized by exsanguinations under anesthesia with diethyl ether inhalation on Day 15 of gestation (15 days after copulation), and the numbers of corpora lutea, implantations, live fetuses and dead fetuses were counted. The pre-implantation loss rate ((the number of corpora lutea -the number of implantations)/ the number of corpora lutea ×100) and the post-implantation loss rate (the number of dead fetuses/the number of implantations ×100) were calculated.
Statistical analysis
All of the following statistical analyses were conducted using commercially available computer software (SAS system, release 8.2 editions, SAS Institute Japan Ltd., the 5 and 1% levels (two-tailed test).
Mean values and standard deviations were calculated for each parameter. The copulation and fertility indices were analyzed by Fisher's exact test (Fisher and Yates, 1963) , and pre-and post-implantation loss rates were analyzed by Steel's test (Steel, 1959) in the female fertility study. Other parameters in the female fertility study and every parameter in the 2-and 4-week repeateddose toxicity studies were analyzed for homogeneity of variance by Bartlett's test (Bartlett, 1937) . For homogeneous data, analysis with Dunnett's test (Dunnett, 1964) was performed, while Steel's test was performed for heterogeneous data.
RESULTS

Repeated-dose toxicity studies (2-and 4-week studies)
Clinical observations, body weight, food consumption and estrous cycle
The clinical condition (clinical observations, body weight, food consumption and estrous cycle) in the 2week study is summarized in Table 1 . Four animals receiving 2.0 mg/kg were found dead from Day 11 to 14 of dosing. In the surviving animals, emaciation, a decrease in locomotor activity, an irregular estrous cycle, a decrease in body weight and/or a decrease in food consumption were observed in the 1.0 and 2.0 mg/kg groups.
The clinical condition in the 4-week study is summarized in Table 2 . A decrease in food consumption was observed in the 0.5 mg/kg group.
Gross pathology and organ weights
In gross pathology, no abnormalities attributable to the dosing were observed in the CDDP-treated groups in the 2-and 4-week studies. In the 2-week study, decreases in the absolute and relative uterus weight were observed in the 1.0 and 2.0 mg/kg groups (Table 3 ). There were no statistically significant differences in organ weights between the control group and the CDDP-treated groups in the 4-week study (Table 4 ).
Histopathology
shown in Table 5 . In the ovary, a decrease in large follicle and increases in atresia of medium and large follicles were observed in the 1.0 and 2.0 mg/kg groups (Fig. 2 ). In particular, apoptotic cell death of granulosa cells was detected in atresia of medium follicle (Fig. 2D ). In addition, a decrease in currently formed corpus luteum was observed in the 2.0 mg/kg group. Atrophy of the uterus, tration in the vagina were observed in the 1.0 and 2.0 mg/ kg groups.
In the 4-week study, histopathological findings are shown in Table 6 . Decreases in small and/or large follicles were observed in the 0.25 and 0.5 mg/kg groups, and an increase in atresia of large follicle was also observed in the 0.5 mg/kg group. In the uterus and vagina, no marked changes were observed in the CDDP-treated groups.
Female fertility study
The results of the female fertility study are summarized in Table 7 . In the 1.0 mg/kg group, a decrease in locomotor activity and emaciation were observed in the pre-mating period and mating period, respectively. Suppression of body weight gain was observed during the gestation period in the 0.5 mg/kg group. In the 1.0 mg/kg group, a decrease in body weight and suppression of body weight gain were observed in the pre-mating period and gestation period, respectively.
In the estrous cycle observation, no abnormalities attributable to dosing were observed in the CDDP-treat-es were observed, the copulation and fertility indices in the 1.0 mg/kg group tended to be lower than those in the control group. A statistically significant increase in the post-implantation loss rate (early death) was observed in decrease in the number of live fetuses was noted in the were observed in the number of corpora lutea and implantations.
DISCUSSION
Two and 4-week repeated intraperitoneally dose toxicity studies and the female fertility study of CDDP were a): estrous cycle was longer than 5 days, or was persistent diestrus.
Vol. 34 Special Issue I SP76 conducted in rats. The dose levels were 0.25, 0.5, 1.0 and 2.0 mg/kg for the 2-week study, and 0.125, 0.25 and 0.5 mg/kg for the 4-week study. In the female fertility study, CDDP was administered to rats at dose levels of 0.25, 0.5 and 1.0 mg/kg from 14 days prior to the initiation of mating, throughout the mating period until Day 7 of gestation.
In the 2-week study, a decrease in large follicle, an increase in atresia of follicle and/or a decrease in current-ly formed corpus luteum were observed on ovarian histopathology in the 1.0 and 2.0 mg/kg groups. In addition, atrophy of the uterus and vaginal epithelium, and/or irregular estrous cycle in the 1.0 and 2.0 mg/kg groups were observed. In histopathological examination on ovary in the 4-week study, a decrease in follicles and/or an increase in atresia were observed in the 0.25 and 0.5 mg/ kg groups. In the female fertility study, the copulation and fertility indices in the 1.0 mg/kg group tended to be lower than those in the control group, and an increase in the post-implantation loss rate and/or a decrease in the number of live fetuses were observed in the 0.5 and 1.0 mg/kg groups. As for the effects of CDDP on rat ovary, decreases in primordial follicles and Müllerian inhibiting substance, which is produced by the primordial and small ovarian follicles, were observed after a single dose of CDDP (Borovskaya et al., 2004; Yucebilgin et al., 2004; Yeh et al., 2006) . Repeated dosing of CDDP during 1 or 2 estrous cycles in rats induces a decrease in the total number of follicles and large follicles are more sensitive to the toxic effects of CDDP than small follicles (Shinagawa, 1998; Matsuo et al., 2007) . However, the mechanism of CDDP ovarian toxicity is not well known. Cyclophosphamide (CP), an antitumor drug, induces ovarian toxicity including a loss of follicles or follicular atresia in rats (Shiromizu et al., 1984; Ataya et al., 1985 Ataya et al., , 1989 like CDDP. In addition, CP induces ovarian follicle damage by causing granulosa cell apoptosis in vit- No. of implantations 13.9 ± 4.4 14.5 ± 3.2 13.6 ± 2.3 11.0 ± 4.5
Pre-implantation loss (%) 13.3 ± 22.9 12.5 ± 13.5 7.5 ± 4.9 29.0 ± 25.5
Post-implantation loss (%) 6.2 ± 6.9 13.1 ± 20. ro (Ataya et al., 1990) and in vivo (Lopez and Luderer, 2004) , and the death of granulosa cells triggers follicular atresia (Rajakoski, 1960; Hughes and Gorospe, 1991) . CDDP and CP act on DNA chain and cause cell injury (Zwelling and Kohn, 1979; Yerushalmi and Yagil, 1980; Kaspárková and Brabec, 1995) . In the present study, rats receiving CDDP at higher doses showed an increase of follicular atresia and a decrease of follicles, as well as apoptotic changes in the granulosa cells of the medium follicles. Therefore, it is possible that CDDP acts on the DNA of granulosa cells and causes follicular atresia by apoptosis of granulosa cells followed by a decrease in all categories of follicle in the rat ovary. CDDP treatment induced a decrease in follicle and an increase in atresia of follicle in the present 4-week repeated-dose toxicity study, while it was reported that no histopathological abnormalities attributable to CDDP were observed in the ovary after 35 days of repeated intraperi-toneal dosing at 0.648 mg/kg (Tsubosaki et al., 1981) . The reason for this discrepancy is not clear. In the present study, we focused our attention on how the number of follicles varies with the estrous cycle, because the number and size distribution of follicles changes in each phase of and Kirkpatrick- Keller, 1984) . Moreover, PCNA immunostaining was performed so that the small follicles could be easily observed (Muskhelishvili et al., 2005) . Conse-ings were detected in the present study.
An increase in the post-implantation loss rate (early death) was observed in rats receiving 0.5 and 1.0 mg/kg in the female fertility study as previously reported (Anabuki et al., 1982) . In addition, total litter loss and a decrease in the number of live fetuses were observed in rats receiving 1.0 mg/kg. CDDP is potentially lethal for embryos (Keller and Aggarwal, 1983.) ; Therefore, it is thought that lethal embryo effect of CDDP.
In the female fertility study, the copulation and fertility indices in rats receiving 1.0 mg/kg tended to be lower than those in the control animals. In the 2-week repeateddose toxicity study, females receiving 1.0 mg/kg showed decreased follicle and increased follicular atresia. Therefore, it is possible that a tendency to decrease copulation and fertility indices may be attributable to a decrease in follicle resulting in a sexual hormone imbalance. The decrease in uterine weight and atrophy of the uterus observed in the 2-week study possidamage caused by CDDP dosing, because the decrease in uterine weight followed the withdrawal of estrogen, which is mainly produced in rats by granulosa cells in ovarian follicles (Morikawa et al., 1982) .
In conclusion, histopathological changes attributable to CDDP dosing were detected by the detailed observation of rat ovary in the 2-week study. Therefore, it is concluded that a 2-week administration period is sufficient for evaluation of ovarian toxicity of CDDP, and should predict alterations in the female reproductive function in the female fertility study.
